Beijing Tiantan Biological Products Corp Ltd (600161) — Capital Reinvestment Ratio
Beijing Tiantan Biological Products Corp Ltd (600161) has a Capital Reinvestment Ratio of 0.39x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥318.80 Million) in capital expenditures (CN¥125.07 Million). See 600161 equity to assets ratio to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Beijing Tiantan Biological Products Corp Ltd Capital Reinvestment Ratio (1998–2024)
This chart tracks Beijing Tiantan Biological Products Corp Ltd's Capital Reinvestment Ratio across 27 annual periods. Check Beijing Tiantan Biological Products Corp (600161) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Beijing Tiantan Biological Products Corp Ltd (1998–2024)
Year-by-year Capital Reinvestment Ratio for Beijing Tiantan Biological Products Corp Ltd from 1998 to 2024. For live market cap and broader valuation context, see 600161 market cap.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 1.30x | CN¥819.78 Million | CN¥1.07 Billion | ▲ +189.2% |
| 2023 | 0.45x | CN¥2.39 Billion | CN¥1.08 Billion | ▼ -62.6% |
| 2022 | 1.20x | CN¥1.13 Billion | CN¥1.35 Billion | ▲ +4.2% |
| 2021 | 1.15x | CN¥980.35 Million | CN¥1.13 Billion | ▲ +33.1% |
| 2020 | 0.87x | CN¥702.11 Million | CN¥608.91 Million | ▲ +5.9% |
| 2019 | 0.82x | CN¥642.47 Million | CN¥526.23 Million | ▲ +88.9% |
| 2018 | 0.43x | CN¥677.92 Million | CN¥293.90 Million | ▼ -34.6% |
| 2017 | 0.66x | CN¥218.39 Million | CN¥144.87 Million | ▲ +35.7% |
| 2016 | 0.49x | CN¥428.37 Million | CN¥209.39 Million | ▼ -23.0% |
| 2015 | 0.64x | CN¥473.26 Million | CN¥300.57 Million | ▼ -34.6% |
| 2014 | 0.97x | CN¥477.95 Million | CN¥464.16 Million | ▲ +0.3% |
| 2013 | 0.97x | CN¥566.43 Million | CN¥548.37 Million | ▼ -25.0% |
| 2012 | 1.29x | CN¥432.00 Million | CN¥557.87 Million | ▼ -36.5% |
| 2011 | 2.04x | CN¥353.15 Million | CN¥718.67 Million | ▲ +26.4% |
| 2010 | 1.61x | CN¥184.85 Million | CN¥297.54 Million | ▲ +277.4% |
| 2009 | 0.43x | CN¥448.23 Million | CN¥191.17 Million | ▼ -21.6% |
| 2008 | 0.54x | CN¥276.39 Million | CN¥150.31 Million | ▲ +25.8% |
| 2007 | 0.43x | CN¥153.55 Million | CN¥66.40 Million | ▼ -6.6% |
| 2006 | 0.46x | CN¥154.36 Million | CN¥71.50 Million | ▲ +53.3% |
| 2005 | 0.30x | CN¥131.69 Million | CN¥39.78 Million | ▼ -61.3% |
| 2004 | 0.78x | CN¥110.11 Million | CN¥85.89 Million | ▼ -45.5% |
| 2003 | 1.43x | CN¥62.93 Million | CN¥90.02 Million | ▲ +246.6% |
| 2002 | 0.41x | CN¥84.38 Million | CN¥34.83 Million | ▼ -60.9% |
| 2001 | 1.06x | CN¥46.49 Million | CN¥49.09 Million | ▲ +14.9% |
| 2000 | 0.92x | CN¥47.90 Million | CN¥44.04 Million | ▼ -9.7% |
| 1999 | 1.02x | CN¥42.58 Million | CN¥43.34 Million | ▼ -58.1% |
| 1998 | 2.43x | CN¥23.71 Million | CN¥57.61 Million | — |